logo
logo

Biofidelity Raises $23M In Series A+ Financing Led By Octopus Ventures To Launch Aspyre Technology

Feb 01, 2022•over 3 years ago

Amount Raised

$23 Million

Round Type

series a

Cambridge

Description

Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors. The investment will fund the upcoming launch of ASPYRE-Lung, the company's first commercial diagnostic assay based on its breakthrough molecular technology.

Company Information

Company

Biofidelity

Location

Cambridge, Maryland, United States

About

Biofidelity is a pioneer in molecular diagnostics whose mission is to unlock the benefits of precision medicine for all patients by increasing access to early detection, precision diagnosis and routine monitoring with its revolutionary technologies. Founded in 2019 in Cambridge, UK, Biofidelity is a rapidly growing private company that recently expanded to include both a U.S. headquarters and state-of-the-art clinical cancer diagnostic laboratory located in Research Triangle Park, North Carolina. For more information, visit biofidelity.com or connect on LinkedIn.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech